503A, 503B or a Marketplace? Sourcing Compounded GLP-1s at Scale

Why a telehealth GLP-1 program runs on 503A, and where it breaks

The U.S. Food and Drug Administration (FDA) describes a Section 503A pharmacy as one whose drugs "must be compounded based on the receipt of valid patient-specific prescriptions" (FDA). A telehealth order is exactly that: one patient, one prescription, one shipment. Section 503B outsourcing facilities are different: they register with FDA and may distribute against a patient-specific prescription or against a provider's order that is not for an identified patient (FDA, FDA outsourcing facilities). That makes them a natural fit for clinic stock, not for a daily stream of named-patient subscriptions.

For GLP-1s specifically, FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list; as of October 2026 the announcement page shows no final determination (FDA). For a telehealth GLP-1 brand, that leaves vetted 503A pharmacies as the working supply; the question is how many, and how they are wired together.

One 503A pharmacy breaks a program at scale in three places, and adding pharmacies by direct contract adds a provider agreement, an integration and an invoice each time:

• A single point of failure. A stockout or a rejected order stops every refill queued behind it.
• No price leverage. One pharmacy sets the price, and buyers report increases once a pharmacy decides a brand's volume is small.
• State gaps. A pharmacy that cannot ship to a state leaves that state's patients unserved, or forces a second integration.

503A, 503B, direct contracts or a marketplace: how the options compare

How AffinityRx solves GLP-1 sourcing at scale

AffinityRx is a multi-pharmacy routing platform with one login, one invoice, one order history and one support contact across every pharmacy, plus an API.

• Failover is live. Set a primary pharmacy plus second and third favorites. If the primary is out of stock or rejects the order, it moves to the next favorite. The prescriber reviews and signs the order for the new pharmacy before it is sent. Details are on the order routing page.
• Price visible before ordering. The same medication from several pharmacies sits side by side, and the price is set at signing. Clinics typically save about 10% versus their current price. In AffinityRx prices as of October 1, 2026, across 13 semaglutide and tirzepatide vial SKUs that each had 3+ pharmacies pricing them, the lowest price averaged 9.8% below the median. One weight-loss telehealth brand's per-vial compounded tirzepatide cost decreased after comparing pharmacies.
• Depth behind the second favorite. 10+ licensed compounding pharmacies, 250+ SKUs, and turnaround shown per pharmacy (about 1 day for some, up to 5 for others).
• State rules handled. The eligibility check applies state board rules, not just ship-to states. Most SKUs are available in all 50 states, and a gap is prioritized for sourcing.
• Engineering lift. The headless API integration is about 1 day of developer work, with a test order the same day and Live access depends on your organization's access settings.
• Coming next. Proactive auto-routing to in-stock pharmacies launches Q4 2026, live stock and backorder status Q1 2027, and 503B facilities for clinic stock Q4 2026 to Q1 2027.

The case builds with volume, at hundreds to thousands of scripts a month; a brand with a few dozen GLP-1 patients and no stockouts has less to gain. See the telehealth weight-loss brand page and the semaglutide page.

Printable worksheet: supply mix worksheet

Print this worksheet and complete it with your own records.

Fill in each line before deciding how many pharmacies to wire up.

1. GLP-1 scripts per month: ________
2. Share of those scripts sent to the largest pharmacy: ________ %
3. Refills affected if that pharmacy is out for one week: ________
4. States you ship to that the largest pharmacy cannot serve: ________
5. Need for clinic stock (office use) in the next 12 months? [ ] yes [ ] no
6. Price gap between your current quote and the lowest quote shown for the same medication: ________

High numbers on lines 2 and 3 are the case for a second and third pharmacy; a gap on line 6 is the case for comparing prices side by side.

FAQs

Book a demo

If one pharmacy carries your whole GLP-1 program, see how favorites, failover and side-by-side prices change that in a demo: press the Book a demo button on the right side of this page. For the objections buyers raise before switching, read AffinityRx objections answered.

Sources

• FDA: Human drug compounding laws and policies, reviewed October 2026
• FDA: Information for outsourcing facilities, reviewed October 2026
• FDA: FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, reviewed October 2026